The therapeutic potential of a venomous lizard: The use of glucagon-like peptide-1 analogues in the critically ill

Adam M. Deane, Marianne J. Chapman, Michael Horowitz

Research output: Contribution to journalComment / DebateOtherpeer-review

7 Citations (Scopus)


Glucagon-like peptide-1 (GLP-1), a principal mediator of the postprandial insulinotropic response in health, has a half-life of minutes. The saliva of the Gila monster contains exendin-4, a structural analogue of human GLP-1, but with a much longer half-life. A synthetic preparation of exendin-4, exenatide, is suitable for human use and effectively lowers glucose in ambulant type 2 diabetic patients. When compared with insulin, exenatide therapy is associated with a reduction in hypoglycaemic episodes and postprandial glycaemic excursions in this group. Accordingly, GLP-1 analogues are appealing therapies for hyperglycaemia in the critically ill patient and warrant further study.

Original languageEnglish
Article number1004
JournalCritical Care
Issue number5
Publication statusPublished - 21 Oct 2010
Externally publishedYes

Cite this